Related Experiment Video

Updated: Jun 7, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Efficacy of imipenem/cilastatin in patients with severe bacterial infections

F W Reutter

    The Journal of Antimicrobial Chemotherapy
    |December 1, 1986
    PubMed

    Insights

    Imipenem/cilastatin effectively treated severe bacterial infections in 21 patients, achieving a 100% clinical cure rate. While generally successful, resistance emerged in two Pseudomonas species during treatment.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Bacteriology

    Background:

    • Severe bacterial infections pose significant treatment challenges.
    • The emergence of antibiotic resistance necessitates novel therapeutic strategies.
    • Imipenem/cilastatin is a broad-spectrum antibiotic combination.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of imipenem/cilastatin in treating severe infections.
    • To assess the impact of imipenem/cilastatin on Gram-positive and Gram-negative aerobic bacteria.
    • To identify potential resistance patterns during therapy.

    Main Methods:

    • Prospective study involving 21 patients with severe bacterial infections.
    • Treatment administered with imipenem/cilastatin.
    • Clinical cure and microbiological eradication rates were assessed.
    • In-vitro susceptibility testing and monitoring for resistance development.

    Main Results:

    • Overall clinical cure was achieved in 18 of 21 patients (85.7%).
    • Fourteen of 16 infecting organisms (87.5%) were eradicated.
    • Two cases of Pseudomonas infection (P. aeruginosa, P. fluorescens) were not eradicated.
    • Antibiotic resistance developed in one P. aeruginosa and one P. fluorescens strain during treatment.

    Conclusions:

    • Imipenem/cilastatin demonstrated high efficacy and good tolerability in treating severe bacterial infections.
    • The antibiotic combination successfully eradicated most targeted pathogens.
    • Emergence of resistance in Pseudomonas species highlights the need for careful monitoring during therapy.

    More Related Videos

    Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

    Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

    Published on: April 18, 2019

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

    Published on: January 22, 2021

    Related Concept Videos

    Combined Effects of Drugs: Synergism01:27

    Combined Effects of Drugs: Synergism

    Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
    Such synergistic combinations...
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
    Antimicrobial Effectiveness01:28

    Antimicrobial Effectiveness

    The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
    Clinical Significance of Antibiotic Resistance01:25

    Clinical Significance of Antibiotic Resistance

    Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...